|
MX2019010174A
|
|
Glatiramer depot systems for treating progressive forms of multiple sclerosis.
|
|
CN109689082A
|
|
The method for being used to prepare the particle comprising acetic acid copaxone
|
|
CA3035147A1
|
|
Depot systems comprising glatiramer acetate
|
|
WO2017109772A1
|
|
Amorphous form of selexipag
|
|
US2017080044A1
|
|
Sublingual delivery of glatiramer acetate
|
|
US2016355500A1
|
|
Intermediate compounds and process for the preparation of efinaconazole
|
|
EP3259262A1
|
|
Process and intermediates for the preparation of perampanel
|
|
EP3143004A1
|
|
Amorphous form of apremilast
|
|
IL233446D0
|
|
Polymorphs of perampanel
|
|
IL231776D0
|
|
Process and intermediates for the preparation of substituted 2- arylthiazole carboxylic acids
|
|
IL231452D0
|
|
Amorphous form of dolutegravir
|
|
EP2991999A1
|
|
Dapagliflozin lactose co-crystal
|
|
IL229920A
|
|
Intermediate compounds and process for the preparation of lurasidone and salts thereof
|
|
IL228972D0
|
|
Random pentapolymer for treatment of autoimmune diseases
|
|
WO2014016830A1
|
|
Process and intermediates for the preparation of abiraterone acetate
|
|
IL226204D0
|
|
Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium
|
|
IL226042D0
|
|
Intermediate compounds and process for the preparation of fingolimod
|
|
WO2013102897A1
|
|
Polymorphs of perampanel
|
|
IL222826D0
|
|
Polymorphs of alogliptin benzoate
|
|
EP2742051A1
|
|
Amorpous form of the dolutegravir sodium salt
|
